Global Blood Therapeutics Announces Upcoming Investor Webcast to Review GBT440 Data Being Presented at ASH that Support Sickl...
November 30 2016 - 04:05PM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced
that it will host an investor webcast on
Monday, December
5, 2016, at 12:15 p.m. PT/3:15 p.m. ET, to review new data
being presented at the 58th American Society of Hematology (ASH)
Annual Meeting & Exposition Conference in San Diego that
support its GBT440 program in sickle cell disease (SCD). The
investor event will feature members of GBT’s management team and
SCD experts Dr. Jo Howard of Guy’s and St. Thomas’ NHS Foundation
Trust, London, UK, Dr. Wally R. Smith of Virginia Commonwealth
University, and Dr. Jeremy Hobart of Peninsula Schools of Medicine
and Dentistry.
The event will highlight data presented at the ASH meeting from
GBT’s ongoing Phase 1/2 GBT440-001 trial including results of
dosing GBT440 at 900 mg per day in SCD patients for up to 6 months,
and the metabolism of GBT440 in healthy subjects, as well as the
methodology utilized to develop the Patient Reported Outcome (PRO)
tool that will be used in the Company’s planned Phase 3 clinical
trial of GBT440 in SCD patients, titled the HOPE
(Hemoglobin Oxygen Affinity
Modulation to Inhibit HbS
PolymErization) Study.
The investor event will be webcast live and available for replay
from GBT's website at www.globalbloodtx.com in the Investors &
Media section.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage
biopharmaceutical company dedicated to discovering, developing and
commercializing novel therapeutics to treat grievous blood-based
disorders with significant unmet need. GBT is developing its lead
product candidate, GBT440, as an oral, once-daily therapy for
sickle cell disease and expects to initiate its Phase 3 clinical
trial by the end of 2016. GBT is also investigating GBT440 for the
treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a
studies in patients with idiopathic pulmonary fibrosis. To
learn more, please visit: www.globalbloodtx.com.
Forward-Looking Statements
Statements we make in this press release may include statements
that are not historical facts and are considered forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. We intend these forward-looking statements, including
statements regarding the therapeutic potential and safety profile
of GBT440, our ability to implement our clinical development plans
for GBT440, the timing of, and our ability to generate data from,
our ongoing Phase 1/2 clinical trial of GBT440 and our ability to
enroll patients in and begin screening in our HOPE Study, to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and
Section 21E of the Securities Exchange Act and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements reflect our current
views about our plans, intentions, expectations, strategies and
prospects, which are based on the information currently available
to us and on assumptions we have made. We can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved, and furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control including, without limitation, the risks that
our clinical and preclinical development activities may be delayed
or terminated for a variety of reasons, that regulatory authorities
may disagree with our clinical development plans or require
additional studies or data to support further clinical
investigation of our product candidates, and that drug-related
adverse events may be observed in later stages of clinical
development, along with those risks set forth in our Annual Report
on Form 10-K for the fiscal year ended December 31, 2015, and in
our Quarterly Reports on Form 10-Q for the quarters ended March 31,
2016, June 30, 2016 and September 30, 2016, as well as discussions
of potential risks, uncertainties and other important factors in
our subsequent filings with the U.S. Securities and Exchange
Commission. Except as required by law, we assume no obligation to
update publicly any forward-looking statements, whether as a result
of new information, future events or otherwise.
Contact Information:
Myesha Lacy (investors)
Global Blood Therapeutics
650-351-4730
investor@globalbloodtx.com
Julie Normart (media)
BrewLife
415-946-1087
media@globalbloodtx.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2023 to Mar 2024